EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder

Benzinga08-13

On Tuesday, Adial Pharmaceuticals Inc. (NASDAQ:ADIL) announced a collaboration with Boudicca Dx, LLC, a global precision medicine testing accelerator. Under the agreement, Boudicca will support Adial ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2459084989?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qrHm0iRtvCyH.LW6URUcCA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/0ec2b6f8f15cadf0cb47a83fa188dac3","is_english":true,"pubTime":"2024-08-13 20:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2459084989","market":"us","top_or_hot":-1,"title":"EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder","media":"Benzinga","content":"<div>\n<p>On Tuesday, Adial Pharmaceuticals Inc. (NASDAQ:ADIL) announced a collaboration with Boudicca Dx, LLC, a global precision medicine testing accelerator.\nUnder the agreement, Boudicca will support Adial ...</p>\n\n<a href=\"https://finance.yahoo.com/news/exclusive-adial-pharmaceuticals-advances-regulatory-123028776.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-13 20:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/exclusive-adial-pharmaceuticals-advances-regulatory-123028776.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Tuesday, Adial Pharmaceuticals Inc. (NASDAQ:ADIL) announced a collaboration with Boudicca Dx, LLC, a global precision medicine testing accelerator.\nUnder the agreement, Boudicca will support Adial ...</p>\n\n<a href=\"https://finance.yahoo.com/news/exclusive-adial-pharmaceuticals-advances-regulatory-123028776.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADIL","symbol_name":"Adial Pharmaceuticals","start_time":0,"source_url":"https://finance.yahoo.com/news/exclusive-adial-pharmaceuticals-advances-regulatory-123028776.html","article_id":"2459084989","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qrHm0iRtvCyH.LW6URUcCA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/0ec2b6f8f15cadf0cb47a83fa188dac3"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459084989","pubTimestamp":1723552228,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"On Tuesday, Adial Pharmaceuticals Inc.  announced a collaboration with Boudicca Dx, LLC, a global precision medicine testing accelerator.Under the agreement, Boudicca will support Adial in advancing its technical and regulatory strategy for the company’s companion diagnostic genetic test to ensure it is validated technically and clinically per FDA guidelines as part of Adial’s regulatory strategy for its lead investigational asset, AD04.Also Read: EXCLUSIVE: Adial Pharmaceuticals’ Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4.AD04 is a genetically-targeted, serotonin-3 receptor antagonist therapeutic agent for Alcohol Use Disorder .Adial’s companion diagnostic is intended to assist AD04 in identifying potential patients and recruiting for the planned Phase 3 program.This article EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder originally ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADIL":"Adial Pharmaceuticals","GENE":"基因技术ADR","BK4125":"广播","BK4007":"制药","BK4121":"生命科学工具和服务","AUD":"Audacy Inc."},"translate_title":"独家：Adial Pharmaceuticals为其酒精使用障碍主导项目推进伴随诊断基因检测的监管策略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADIL":1,"AUD":1,"GENE":1},"content_text":"On Tuesday, Adial Pharmaceuticals Inc. (NASDAQ:ADIL) announced a collaboration with Boudicca Dx, LLC, a global precision medicine testing accelerator.\nUnder the agreement, Boudicca will support Adial in advancing its technical and regulatory strategy for the company’s companion diagnostic genetic test to ensure it is validated technically and clinically per FDA guidelines as part of Adial’s regulatory strategy for its lead investigational asset, AD04.\nAlso Read: EXCLUSIVE: Adial Pharmaceuticals’ Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4.\nAD04 is a genetically-targeted, serotonin-3 receptor antagonist therapeutic agent for Alcohol Use Disorder (AUD).\nAdial’s companion diagnostic is intended to assist AD04 in identifying potential patients and recruiting for the planned Phase 3 program.\nCary Claiborne, President and Chief Executive Officer of Adial, commented, “As we continue to prepare for the Phase 3 study for AD04, this agreement with Boudicca Dx is another key component toward achieving clinical success and is expected to support our next FDA interaction.”\nKelly Gordon commented, “The Boudicca Dx team is excited to support the development of a first-in-class companion diagnostic test for AD04, a precision medicine designed to treat patients with Alcohol Use Disorder.  This disease affects more than 30 million people in the US alone and causes 3 million deaths worldwide each year. There is a high unmet need for a targeted therapy and its companion diagnostic test.”\nPrice Action: ADIL stock closed at $0.97 on Monday.\nRead Next:\n\nEXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder.\n\n\"ACTIVE INVESTORS' SECRET WEAPON\" Supercharge Your Stock Market Game with the #1 \"news & everything else\" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!\nGet the latest stock analysis from Benzinga?\n\nThis article EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459084989"}